Signant Health Acquires Ametris to Build Integrated eCOA and Digital Outcome Measures Platform

Signant Health has acquired Ametris, formerly known as ActiGraph, in a move designed to unite electronic clinical outcome assessments with wearable-derived digital outcome measures on a single platform.¹

The combined offering is intended to give sponsors a way to integrate what patients report about how they feel and function with continuous, sensor-based data collected in their natural environments—without managing multiple vendors or reconciling disparate datasets.

Clinical trials increasingly require multiple lines of evidence to demonstrate meaningful treatment benefit, and sponsors have historically had to navigate complex integration challenges to bring those data streams together. Signant says the acquisition addresses that gap directly, with near-term priorities including unified data flows, coordinated deployment tools, and integrated analytics.

Longer-term, the company points to artificial intelligence and machine learning applications that could identify patterns across both modalities and enable novel composite outcome measures.

"This acquisition represents our commitment to advancing what's possible in clinical evidence generation—building an end-to-end platform that integrates what patients say and what their bodies show," said Roger Smith, chief executive officer of Signant, in a press release. "This is particularly valuable in CNS and other complex therapeutic areas where sponsors need multiple lines of evidence to demonstrate meaningful benefit."

Ametris brings two decades of experience developing regulatory-aligned wearable-derived measures of physical activity and function. Its capabilities are seen as complementary to Signant's established strength in clinical outcome assessments, with the combined expertise spanning both self-reported and sensor-based measurement.

"Joining Signant allows us to accelerate our vision of truly integrated multimodal evidence generation," added Jeremy Wyatt, chief executive officer of Ametris, in the release. "This benefits our customers through simplified vendor management today and seamless platform integration and converged workflows as our roadmap progresses."

Building the case for digital measures

Back in February, Applied Clinical Trials caught up with Wyatt at the 2026 SCOPE Summit for an exclusive interview in which he discussed operational best practices for integrating wearables into clinical trials and the broader case for digital endpoints across drug development programs.

On the operational side, Wyatt emphasized that device selection and workflow design need to be driven by patient burden reduction from the outset. In oncology in particular, where patients are managing comorbidities and significant physical and emotional strain, the technology itself should never create friction.²

Battery management, device logistics, missing data handling, and global site support all need to be addressed early and robustly. Along with that, digital endpoint vendors need to be involved in protocol planning before the design is locked.

"Sponsors need to involve digital endpoint vendors early in protocol planning to ensure the measurement strategy is fit for purpose from the beginning—not added as an afterthought," Wyatt said in the interview.

On the broader value of digital endpoints, Wyatt pointed to both sensitivity and efficiency as key advantages. Continuous data collection in real-world environments captures a more complete picture of patient functioning than episodic site visit measurements, and the statistical power of those measures can meaningfully affect study design.

In one Phase III pivotal study, Wyatt noted, the use of digital measures enabled a 50% reduction in the required patient population.

Regulatory alignment, he added, is essential to making these gains repeatable across programs.³

“Clear regulatory expectations around validation and evidence generation allow digital endpoints to be repeatable and acceptable across multiple programs, not just one study. That consistency is essential if we want to scale digital measures across clinical development."

The acquisition closes a gap that Wyatt had identified as a persistent challenge in the field—and positions the combined company to deliver on the kind of integrated, sponsor-ready evidence package that regulators and the industry have been moving toward.

References

1. Signant Health Acquires Ametris to Create an End-to-End eCOA and Digital Outcome Measures Platform. News release. Signant Health. May 14, 2026. Accessed May 14, 2026. https://www.prnewswire.com/news-releases/signant-health-acquires-ametris-to-create-an-end-to-end-ecoa-and-digital-outcome-measures-platform-302771426.html

2. SCOPE Summit 2026: Reducing Patient Burden Is the Foundation of Wearable Success in Oncology. Applied Clinical Trials. February 6, 2026. Accessed May 14, 2026. https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-reducing-patient-burden-foundation-wearable-success-oncology

3. SCOPE Summit 2026: Advancing Digital Endpoints Through Performance and Regulatory Alignment. Applied Clinical Trials. February 12, 2026. Accessed May 14, 2026. https://www.appliedclinicaltrialsonline.com/view/scope-summit-2026-advancing-digital-endpoints-regulatory-alignment